Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 8Lung Neoplasms 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Multiple Myeloma 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Glioblastoma 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroblastoma 2Meningioma 2Lymphoma, B-Cell 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Ipilimumab 5Nivolumab 4pembrolizumab 3sargramostim 2fludarabine 2binimetinib 2aldesleukin 2Interleukin-2 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 2trametinib 1tebentafusp 1sotrastaurin 1montanide ISA 51 1incomplete Freund's adjuvant 1glembatumumab vedotin 1fludarabine phosphate 1entrectinib 1Valproic Acid 1Tramadol 1Thalidomide 1Temozolomide 1Solutions 1Ruthenium-106 1Radiotherapy 1RNA, Messenger 1Protein Kinase C 1Melphalan 1Magnetic Resonance Spectroscopy 1Ibuprofen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uveal Melanoma × Magnetic Resonance Spectroscopy × Clear all
NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡